Source: BrainStorm Cell Therapeutics Inc.
Posted: August 14, 2007 8:30 am ET
Summary:
BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), a leading developer of adult stem cell technologies and therapeutics, is pleased to announce preliminary results from its first safety supporting experiment. On February 8, 2007 in laboratories at the University of Navarra, Pamplona, Spain, Prof. Jose Obeso transplanted the subject, a healthy monkey, with BrainStorm`s human bone marrow derived mesenchymal stem cells. The stem cells had been induced to differentiate into neurotrophic factor-producing cells, according to the protocol developed at the Company`s laboratories in Israel.
